AF
IMRX icon

Amalgamated Financial’s Immuneering IMRX Stock Holding History

Amalgamated Financial’s Portfolio IMRX Stock Details IMRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		$8K Buy
+1,219
New +$11.7K ﹤0.01% 2927

Other funds holding IMRX

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Amalgamated Financial's IMRX Position: Q1 2022 in Review

Amalgamated Financial opened a new position in Immuneering (IMRX) in Q1 2022: 1,219 shares worth $8K. The stake represents ﹤0.01% of the portfolio and ranks #2927 among its holdings.

50 funds tracked by Wall St. Rank hold IMRX as of Q1 2022.

  • Amalgamated Financial held 1,219 shares of Immuneering worth $8K as of Q1 2022.
  • Immuneering was a new Amalgamated Financial position in Q1 2022.
  • Immuneering made up ﹤0.01% of Amalgamated Financial's portfolio in Q1 2022, its #2927 holding.
  • 50 funds tracked by Wall St. Rank held Immuneering as of Q1 2022.

Based on Amalgamated Financial's 13F filing for Q1 2022, filed 16 May 2022.